Press Release

Kirkland Advises on Sinovac Biotech’s Going Private Proposal

Kirkland & Ellis is advising a consortium led by Mr. Weidong Yin, the chairman, president and chief executive officer of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac”), a leading provider of biopharmaceutical products in China, and SAIF Partners, in connection with the proposed acquisition of Sinovac. The definitive agreement, which valued the transaction at approximately US$401.8 million, was announced on June 26, 2017. For further information, please see the company press release here.

The Kirkland team is led by Hong Kong corporate partners David Zhang and Henry Yin.